ACI
MCRB icon

AMP Capital Investors’s Seres Therapeutics MCRB Stock Holding History

AMP Capital Investors’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1,206
Closed -$179K – 1202
2018
Q1 		$179K Buy
+1,206
New +$231K ﹤0.01% 1140

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

AMP Capital Investors's MCRB Position: Q2 2018 in Review

AMP Capital Investors sold out of Seres Therapeutics (MCRB) in Q2 2018, closing a stake of 1,206 shares — an estimated $179K sold.

AMP Capital Investors first reported a position in MCRB in Q1 2018 and held it in 1 quarter. The position peaked at $179K in Q1 2018. 78 funds tracked by Wall St. Rank hold MCRB as of Q2 2018.

  • AMP Capital Investors reported no remaining Seres Therapeutics position as of Q2 2018 after selling out during the quarter.
  • AMP Capital Investors sold 1,206 Seres Therapeutics shares in Q2 2018, an estimated $179K.
  • AMP Capital Investors first reported a position in Seres Therapeutics in Q1 2018 and held it in 1 quarter.
  • AMP Capital Investors's Seres Therapeutics position peaked at $179K in Q1 2018.
  • 78 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2018.

Based on AMP Capital Investors's 13F filing for Q2 2018, filed 13 Aug 2018.